Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivabradine

AstraZeneca AZ

AZ’s Farxiga gets heart failure prevention okay from FDA

Important win for AZ as it chases down market leader Jardiance

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

- PMLiVE

Amgen wins Enbrel patent case, knocking back Sandoz’s biosimilar plan

Shares up 6% following court ruling

Novartis day

Blow for Entresto in latest heart failure trial

Aim of being first in HFpEF in serious doubt

- PMLiVE

Amgen gets block on sales of Repatha rival in Germany

Part of ongoing battle with Sanofi and Regeneron

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

- PMLiVE

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links